Comparison of Vaccination with Measles-Mumps-Rubella Vaccine at 9, 12, and 15 Months of Age

Journal of Infectious Diseases

Volumn 189, Issue SUPPL. 1, 2004, Pages

  Redd, Stephen C ^a,d   King, Gail E ^a   Heath, Janet L ^b   Forghani, Baghar ^c   Bellini, William J ^b   Markowitz, Lauri E ^a  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE; MUMPS VACCINE; RUBELLA VACCINE;

AGE DETERMINATION; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MEASLES; MOTHER; MUMPS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RUBELLA; SEROCONVERSION; VACCINATION;

EID: 2442473306     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/378691     Document Type: Article

References (29)

1. Orenstein WA, Markowitz L, Preblud SR, Hinman AR, Tomasi A, Bart KJ. Appropriate age for measles vaccination in the United States. Dev Biol Stand 1986; 65:13-21.
2. Black FL, Berman LL, Borgono JM, et al. Geographic variation in infant loss of maternal measles antibody and in prevalence of rubella antibody. Am J Epidemiol 1986; 124:442-52.
3. Reilly CM, Stokes J Jr, Buynak EB, Goldner H, Hilleman MR. Living attenuated measles-virus vaccine in early infancy. Studies of the role of passive antibody in immunization. N Engl J Med 1961; 265:165-9.
4. Sato H, Albrecht P, Reynolds DW, Stagnio S, Ennus FA. Transfer of measles mumps and rubella antibodies from mother to infant. Its effect on measles , mumps, and rubella immunization. Am J Dis Child 1979; 133:1240-3.
5. Landor M. Maternal-fetal transfer of immunoglobulins. Ann Allergy Asthma Immunol 1995; 74:279-83.
6. Krugman S, Giles GP, Friedman H, Stone S. Studies on immunity to measles. J Pediatr 1965; 66:471-88.
7. Reilly CM, Stokes J, Buynak EB, Goldner H, Hilleman MR. Living attenuated measles-virus vaccine in early infancy. Studies of the role of passive antibody in immunization. N Engl J Med 1960; 263:230-3.
8. American Academy of Pediatrics. Report of the Committee on the Control of Infectious Diseases. Evanston, IL: American Academy of Pediatrics, 1964:8.
9. Krugman S, Giles JP, Friedman H, Stone S. Studies on immunity to measles. J Pediatr 1965; 66:471-88.
10. Centers for Disease Control and Prevention. Recommendations of the Public Health Service Advisory Committee on Immunization Practice. MMWR Morb Mortal Wkly Rep 1965; 14:64-7.
11. Centers for Disease Control and Prevention. Measles vaccine: recommendations of the Public Health Service Advisory Committee on Immunization Practice. MMWR Morb Mortal Wkly Rep 1976; 25: 359-60, 365.
12. Maldonado YA, Lawrence EC, DeHovitz R, Hartzell H, Albrecht P. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity. Pediatrics 1995; 96:447-50.
13. Markowitz LE, Albrecht P, Rhodes P, et al. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Pediatrics 1996; 97:53-8.
14. Hummel KB, Erdman DD, Heath J, Bellini WJ. Baculovirus expression of the nucleoprotein gene of measles virus and the utility of the recombinant protein in diagnostic enzyme immunoassays. J Clin Microbiol 1992; 30:2874-80.
15. Tamin A, Rota PA, Wang ZD, Heath JL, Anderson LJ, Bellini WJ. Antigenic analysis of current wild type and vaccine strains of measles virus. J Infect Dis 1994; 170:795-801.
16. Forghani B, Schmidt NJ. Antigen requirements, sensitivity, and specificity of enzyme immunoassays for measles and rubella viral antibodies. J Clin Microbiol 1979; 9:657-64.
17. SAS Institute. SAS/STAT7 software: changes and enhancements through release 6.12. Gary, NC: SAS Institute, 1997:421-530.
18. Singh R, John TJ, Cherian T, Raghupathy P. Immune response to measles, mumps, and rubella vaccine at 9, 12, and 15 months of age. Indian J Med Res 1994; 100:155-9.
19. Forleo-Neto E, Carvalho ES, Fuentes ICP, Precivale MS, Forleo LHA, Farhat CK. Seroconversion of a trivalent measles, mumps, and rubella vaccine in children aged 9 and 15 months. Vaccine 1997; 15:1898-901.
20. Schoub BD, Johnson S, McAnerney JM, et al. Measles, mumps, and rubella immunization at nine months in a developing country. Pediatr Infect Dis J 1990; 9:263-7.
21. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998; 47(RR-8):1-57.
22. Cohn ML, Robinson ED, Faerber M, et al. Measles vaccine failures: lack of sustained measles-specific immunoglobulin G responses in revaccinated adolescents and young adults. Pediatr Infect Dis J 1994; 13: 34-8.
23. Ward BJ, Boulianne N, Ratman S, Guiot MC, de Serres G. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 1995; 172:1591-5.
24. Stetler HC, Orenstein WA, Bernier RH, et al. Impact of revaccinating children who initially received measles vaccine before 10 months of age. Pediatrics 1986; 77:471-6.
25. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42.
26. Shasby DM, Shope TC, Downs H, Hermann KL, Polkowski J. Epidemic measles in a highly vaccinated population. N Engl J Med 1977; 296: 585-9.
27. Davis RM, Whitman ED, Orenstein WA, Preblud SR, Markowitz LE, Hinman AR. A persistent outbreak of measles despite appropriate prevention and control measures. Am J Epidemiol 1987; 126:438-49.
28. Rota J, Heath JL, Rota PA, et al. Molecular epidemiology of measles virus: identification of pathways of transmission and implications for measles elimination. J Infect Dis 1996; 173:32-7.
29. Centers for Disease Control and Prevention. Measles - United States, 1996, and the interruption of indigenous transmission. MMWR Morb Mortal Wkly Rep 1997; 46:242-6.